Shield Therapeutics PLC (STX) Earns Buy Rating from Liberum Capital
Shield Therapeutics PLC (LON:STX)‘s stock had its “buy” rating reissued by Liberum Capital in a research note issued to investors on Thursday. They currently have a GBX 245 ($3.16) price target on the stock. Liberum Capital’s price objective would suggest a potential upside of 55.56% from the stock’s previous close.
Several other brokerages have also recently commented on STX. FinnCap started coverage on Shield Therapeutics PLC in a research report on Thursday, September 7th. They set a “buy” rating and a GBX 270 ($3.49) price target for the company. Peel Hunt reiterated a “buy” rating and set a GBX 220 ($2.84) price target on shares of Shield Therapeutics PLC in a research report on Thursday, July 6th.
Shield Therapeutics PLC (LON STX) remained flat at GBX 157.50 during midday trading on Thursday. The company’s stock had a trading volume of 2,500 shares. The stock has a 50-day moving average price of GBX 157.50 and a 200-day moving average price of GBX 163.10. Shield Therapeutics PLC has a 52 week low of GBX 152.25 and a 52 week high of GBX 177.00. The firm’s market cap is GBX 170.10 million.
About Shield Therapeutics PLC
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.
Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.